Novartis has reported positive topline outcomes from the multicentre Phase IIIB APPULSE-PNH trial of oral Fabhalta (iptacopan) for treating adults with paroxysmal nocturnal haemoglobinuria (PNH).
In PNH patients experiencing substantial extravascular hemolysis while receiving ravulizumab, zaltenibart monotherapy resulted in sustained clinically meaningful improvements in both hemoglobin ...
Read before using this medicine. Ultomiris contains the active ingredient ravulizumab rch. For more information, see Section 1. Why am I using Ultomiris? in the full CMI. 2. What should I know ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback